Fri Sep 20 09:07:34 UTC 2024: ## Bausch + Lomb Stock Surges on Strong Earnings and Analyst Optimism

**New York, NY – September 20, 2024** – Bausch + Lomb Co. (NYSE: BLCO) shares opened trading Wednesday at $19.30, a significant jump from the previous day’s closing price of $18.56. The stock continued its upward trajectory throughout the day, ultimately closing at $20.06 with a trading volume of 296,280 shares.

The surge in Bausch + Lomb’s stock price can be attributed to several factors, including strong quarterly earnings and positive analyst sentiment. The company reported $0.13 EPS for the quarter ended July 31st, meeting analyst estimates and surpassing last year’s performance. Revenue also came in at $1.22 billion, exceeding expectations and showcasing a 17.5% year-over-year increase.

Analysts have also expressed optimism about Bausch + Lomb’s future. While Needham & Company LLC maintained a “hold” rating on the stock, several other firms have raised their price targets. Evercore, for example, increased their target from $15.50 to $17.00, citing the company’s strong performance and future growth potential. Overall, MarketBeat data reveals a “Moderate Buy” consensus rating for BLCO, with an average target price of $18.59.

Adding to the positive sentiment, Bausch + Lomb CEO Brent L. Saunders purchased 32,250 shares of the company’s stock on August 5th at an average cost of $15.66 per share. This insider purchase signals strong confidence in the company’s future prospects.

Institutional investors are also showing increasing interest in Bausch + Lomb. Several hedge funds and other institutional investors have recently bought and sold shares of the company, indicating growing confidence in the stock. Notably, Clearline Capital LP increased its stake in Bausch + Lomb by 136.8% in the second quarter, while Freshford Capital Management LLC expanded its holdings by 29.8% during the fourth quarter.

Bausch + Lomb Corporation operates as an eye health company with a global presence, offering a range of products, including contact lenses, lens care solutions, pharmaceuticals, and surgical devices. The company’s strong financial performance and positive market outlook have fueled investor confidence, driving the recent surge in its stock price.

Read More